Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 15;3(3):462-81.
doi: 10.9745/GHSP-D-15-00116. Print 2015 Sep.

Estimating Contraceptive Prevalence Using Logistics Data for Short-Acting Methods: Analysis Across 30 Countries

Affiliations

Estimating Contraceptive Prevalence Using Logistics Data for Short-Acting Methods: Analysis Across 30 Countries

Marc Cunningham et al. Glob Health Sci Pract. .

Abstract

Background: Contraceptive prevalence rate (CPR) is a vital indicator used by country governments, international donors, and other stakeholders for measuring progress in family planning programs against country targets and global initiatives as well as for estimating health outcomes. Because of the need for more frequent CPR estimates than population-based surveys currently provide, alternative approaches for estimating CPRs are being explored, including using contraceptive logistics data.

Methods: Using data from the Demographic and Health Surveys (DHS) in 30 countries, population data from the United States Census Bureau International Database, and logistics data from the Procurement Planning and Monitoring Report (PPMR) and the Pipeline Monitoring and Procurement Planning System (PipeLine), we developed and evaluated 3 models to generate country-level, public-sector contraceptive prevalence estimates for injectable contraceptives, oral contraceptives, and male condoms. Models included: direct estimation through existing couple-years of protection (CYP) conversion factors, bivariate linear regression, and multivariate linear regression. Model evaluation consisted of comparing the referent DHS prevalence rates for each short-acting method with the model-generated prevalence rate using multiple metrics, including mean absolute error and proportion of countries where the modeled prevalence rate for each method was within 1, 2, or 5 percentage points of the DHS referent value.

Results: For the methods studied, family planning use estimates from public-sector logistics data were correlated with those from the DHS, validating the quality and accuracy of current public-sector logistics data. Logistics data for oral and injectable contraceptives were significantly associated (P<.05) with the referent DHS values for both bivariate and multivariate models. For condoms, however, that association was only significant for the bivariate model. With the exception of the CYP-based model for condoms, models were able to estimate public-sector prevalence rates for each short-acting method to within 2 percentage points in at least 85% of countries.

Conclusions: Public-sector contraceptive logistics data are strongly correlated with public-sector prevalence rates for short-acting methods, demonstrating the quality of current logistics data and their ability to provide relatively accurate prevalence estimates. The models provide a starting point for generating interim estimates of contraceptive use when timely survey data are unavailable. All models except the condoms CYP model performed well; the regression models were most accurate but the CYP model offers the simplest calculation method. Future work extending the research to other modern methods, relating subnational logistics data with prevalence rates, and tracking that relationship over time is needed.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Public-Sector Injectables Prevalence Rate Estimates
FIGURE 2
FIGURE 2
Public-Sector Oral Contraceptive Prevalence Rate Estimates
FIGURE 3
FIGURE 3
Public-Sector Male Condom Prevalence Rate Estimates
FIGURE 4
FIGURE 4
CPR Estimates for Public-Sector Short-Acting Methods
APPENDIX FIGURE 1.
APPENDIX FIGURE 1.
Difference Between Model-Generated and Referent DHS Public Injectables Prevalence Rate
APPENDIX FIGURE 2.
APPENDIX FIGURE 2.
Difference Between Model-Generated and Referent DHS Public Oral Contraceptives Prevalence Rate
APPENDIX FIGURE 3.
APPENDIX FIGURE 3.
Difference Between Model-Generated and Referent DHS Public Condoms Prevalence Rate

Similar articles

Cited by

References

    1. Gruskin S, Ravindran TK; Rights-Oriented Research and Education (RORE) Network for Sexual and Reproductive Health. Realising the ICPD 20 years later: shifting the paradigms for research and education. Glob Public Health. 2014;9(6):647–652. 10.1080/17441692.2014.923014. - DOI - PubMed
    1. Cates W, Jr, Maggwa B. Family planning since ICPD--how far have we progressed? Contraception. 2014;90(6 Suppl):S14–S21. 10.1016/j.contraception.2014.06.025. - DOI - PubMed
    1. Requejo J, Bryce J, Victora C. Building a future for women and children: the 2012 report. Geneva: World Health Organization; 2012. Co-published by UNICEF Available from: http://www.countdown2015mnch.org/documents/2012Report/2012-complete-no-p...
    1. Canning D, Schultz TP. The economic consequences of reproductive health and family planning. Lancet. 2012;380(9837):165–171. 10.1016/S0140-6736(12)60827-7. - DOI - PubMed
    1. Ahmed S, Li Q, Liu L, Tsui AO. Maternal deaths averted by contraceptive use: an analysis of 172 countries. Lancet. 2012;380(9837):111–125. 10.1016/S0140-6736(12)60478-4. - DOI - PubMed

Publication types

Substances